Sees FY23 Crysvita revenue in the range of $325M-$340M. This includes all regions where Ultragenyx will recognize revenue, including the royalties in Europe, which have been ongoing, and the royalties in North America, which began in April 2023. Sees FY23 Dojolvi revenue in the range of $65M-$75M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
- 3 Best Stocks to Buy Now, 8/2/2023, According to Top Analysts
- Ultragenyx initiates dosing in second cohort of Phase 1/2/3 Cyprus2+ study
- Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
